PH12012501542A1 - Treatment of inflammatory bowel diseases with mammal beta defensis - Google Patents

Treatment of inflammatory bowel diseases with mammal beta defensis

Info

Publication number
PH12012501542A1
PH12012501542A1 PH12012501542A PH12012501542A PH12012501542A1 PH 12012501542 A1 PH12012501542 A1 PH 12012501542A1 PH 12012501542 A PH12012501542 A PH 12012501542A PH 12012501542 A PH12012501542 A PH 12012501542A PH 12012501542 A1 PH12012501542 A1 PH 12012501542A1
Authority
PH
Philippines
Prior art keywords
treatment
inflammatory bowel
defensis
bowel diseases
mammal beta
Prior art date
Application number
PH12012501542A
Other languages
English (en)
Inventor
Kjaer Tanja Maria Rosenkilde
Kruse Thomas
Mygind Per Holse
Brinch Karoline Sidelmann
Kjaerulff Soeren
Andersen Birgitte
Original Assignee
Novozymes Adenium Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41530820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12012501542(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes Adenium Biotech As filed Critical Novozymes Adenium Biotech As
Publication of PH12012501542A1 publication Critical patent/PH12012501542A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12012501542A 2008-07-18 2012-07-27 Treatment of inflammatory bowel diseases with mammal beta defensis PH12012501542A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08160761 2008-07-18
EP08162486 2008-08-15
EP08163614 2008-09-03
PCT/EP2009/059253 WO2010007166A2 (en) 2008-07-18 2009-07-17 Treatment of inflammatory bowel diseases with mammal beta defensins

Publications (1)

Publication Number Publication Date
PH12012501542A1 true PH12012501542A1 (en) 2015-11-09

Family

ID=41530820

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12012501542A PH12012501542A1 (en) 2008-07-18 2012-07-27 Treatment of inflammatory bowel diseases with mammal beta defensis

Country Status (20)

Country Link
US (4) US8232242B2 (https=)
EP (2) EP2320930A2 (https=)
JP (2) JP2011528333A (https=)
KR (1) KR20110092325A (https=)
CN (2) CN102247591A (https=)
AP (2) AP2011005538A0 (https=)
AR (2) AR072032A1 (https=)
AU (1) AU2009272681A1 (https=)
BR (2) BRPI0915973A2 (https=)
CA (2) CA2750727A1 (https=)
CL (1) CL2011000099A1 (https=)
EA (2) EA201170219A1 (https=)
IL (2) IL210715A0 (https=)
MX (1) MX2011000568A (https=)
NZ (2) NZ590468A (https=)
PH (1) PH12012501542A1 (https=)
SG (1) SG172709A1 (https=)
TW (2) TW201138810A (https=)
WO (1) WO2010007166A2 (https=)
ZA (1) ZA201100461B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172709A1 (en) 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
US8232248B2 (en) * 2008-07-18 2012-07-31 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
AP2011005537A0 (en) * 2008-07-18 2011-02-28 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins.
KR101329774B1 (ko) * 2010-06-16 2013-11-15 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
CA2832859C (en) 2011-04-15 2020-06-16 Marine Polymer Technologies, Inc. Treatment of disease with poly-n-acetylglucosamine nanofibers
JP6219277B2 (ja) * 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
US10257564B2 (en) * 2013-01-24 2019-04-09 Saturn Licensing Llc Distributed non-real-time content
CN104628864B (zh) * 2013-11-14 2020-04-10 中国医学科学院医药生物技术研究所 一种抗肿瘤融合蛋白EL-defensin、其编码基因和用途
CN109414474B (zh) * 2016-04-29 2024-07-02 诺维信公司 肝脏、胆道和胰腺障碍的治疗
MX2019006848A (es) 2016-12-13 2019-10-07 Defensin Therapeutics Aps Metodos para tratar condiciones inflamatorias de los pulmones.
MX2020004863A (es) * 2017-11-10 2020-10-14 Defensin Therapeutics Aps Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro.
PL3713590T3 (pl) 2017-11-24 2025-09-15 Defensin Therapeutics Aps Ludzka beta 2 defensyna do stosowania w zapobieganiu i leczeniu choroby przeszczep przeciwko gospodarzowi
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
CN113684162B (zh) * 2021-06-03 2024-02-27 江南大学 一种表达小鼠防御素mBD14基因的重组植物乳杆菌及其应用
WO2024225153A1 (ja) * 2023-04-27 2024-10-31 サントリーホールディングス株式会社 免疫活性化用組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6576755B1 (en) * 1997-09-10 2003-06-10 Zymogenetics, Inc. Beta-defensins
DE19957043A1 (de) * 1999-11-26 2001-06-07 Forssmann Wolf Georg Neue Defensine
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
FR2841556B1 (fr) 2002-07-01 2007-07-20 Centre Nat Rech Scient Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments
NZ540506A (en) * 2002-12-19 2008-09-26 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
GB0514482D0 (en) 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
US8895062B2 (en) 2006-01-24 2014-11-25 University Of Maryland, Baltimore Surface-layer protein coated microspheres and uses thereof
KR20100071985A (ko) 2007-09-11 2010-06-29 몬도바이오테크 래보래토리즈 아게 치료제로서의 데펜신 펩티드의 용도
AP2011005537A0 (en) 2008-07-18 2011-02-28 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins.
SG172709A1 (en) 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
US8232248B2 (en) 2008-07-18 2012-07-31 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ 炎症性腸疾患の経口治療
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide

Also Published As

Publication number Publication date
EA201100910A1 (ru) 2012-05-30
US20110251139A1 (en) 2011-10-13
CA2730789A1 (en) 2010-01-21
US8802621B2 (en) 2014-08-12
US20100016230A1 (en) 2010-01-21
AU2009272681A1 (en) 2010-01-21
EP2320930A2 (en) 2011-05-18
JP2011528333A (ja) 2011-11-17
MX2011000568A (es) 2011-02-23
NZ590468A (en) 2012-06-29
NZ593653A (en) 2012-09-28
WO2010007166A2 (en) 2010-01-21
CA2750727A1 (en) 2010-01-21
EP2399600A1 (en) 2011-12-28
US8232242B2 (en) 2012-07-31
IL213680A0 (en) 2011-07-31
JP2011225596A (ja) 2011-11-10
US20140135258A1 (en) 2014-05-15
AP2011005538A0 (en) 2011-02-28
KR20110092325A (ko) 2011-08-17
CN102159233A (zh) 2011-08-17
ZA201100461B (en) 2014-03-26
AR081948A2 (es) 2012-10-31
IL210715A0 (en) 2011-03-31
CN102247591A (zh) 2011-11-23
TW201138810A (en) 2011-11-16
SG172709A1 (en) 2011-07-28
BRPI0915973A2 (pt) 2013-05-07
AR072032A1 (es) 2010-07-28
US9279010B2 (en) 2016-03-08
TW201004640A (en) 2010-02-01
WO2010007166A3 (en) 2010-06-03
BRPI0924481A2 (pt) 2015-08-11
US20120309678A1 (en) 2012-12-06
EA201170219A1 (ru) 2011-08-30
AP2011005755A0 (en) 2011-06-30
CL2011000099A1 (es) 2011-10-07

Similar Documents

Publication Publication Date Title
PH12012501542A1 (en) Treatment of inflammatory bowel diseases with mammal beta defensis
AP2011005537A0 (en) Treatment of inflammatory diseases with mammal beta defensins.
IL200368A0 (en) Treatment of diseases characterized by inflammation
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
PL2056807T3 (pl) Leczenie chorób zakaźnych
SI3045474T1 (sl) Terapevtska sredstva za zdravljenje bolezni povezane z neželeno proliferacijo celic
ZA201009030B (en) Methods of treating inflammatory colon disease
PL2444081T3 (pl) Kompozycja do leczenia chorób zapalnych, zawierająca kwas bosweliowy i kannabidiol
ZA201109502B (en) Novel compound useful for the treatment of degenerative and inflammatory diseases
ZA200905364B (en) Treatment of diseases characterized by inflammation
PT2403503T (pt) Métodos para tratar doenças inflamatórias oculares
GB0700972D0 (en) Treatment of inflammatory disease
WO2010007168A3 (en) Treatment of rheumatoid arthritis with mammal beta defensins
PL2293805T3 (pl) Kompozycja do ssania, do leczenia chorób zapalnych jamy ustnej i gardłowej
IL218001A (en) Pharmaceuticals for the treatment of inflammatory diseases mediated 1 mcp
HUE042736T2 (hu) Gyulladásos vagy autoimmun rendellenességek kezelésének irányítása HOM-1 kifejezés alkalmazásával
PL2113254T3 (pl) Kompozycje do leczenia autoimmunologicznego stanu zapalnego
GB0720976D0 (en) Treatment of inflammatory disease
UA99539C2 (ru) Лечение воспалительных заболеваний кишечника бета-дефензинами человека
WO2008037497A3 (en) Galectin-2 for the treatment of inflammatory diseases of the skin
IL208849A0 (en) Compositions for the treatment of vaginal infections with chronic inflammation
HK1156244A (en) Treatment of inflammatory bowel diseases with mammal beta defensins
HK1156243A (en) Treatment of inflammatory diseases with mammal beta defensins
IL202502A (en) Cxcl11 for the treatment of inflammatory diseases